LipoMedix Appoints New Members to Board of Directors and Creates New Executive Committee
05 August 2019 - 11:35PM
LipoMedix Pharmaceuticals Ltd., a clinical and
development-stage company focused on the development of an
innovative, safe and effective cancer therapy based on liposome
delivery, today announced the addition of Miranda J. Toledano
and Praveen Tyle, Ph.D., to its board of directors. The company
also announced the formation of an executive committee of the board
to enhance governance and support the company’s development. Ms.
Toledano and Dr. Tyle will join Sanjeev Luther, chairman of the
board, on the newly formed executive committee.
“We continue to build LipoMedix’ pharmaceutical
franchise with additional talented directors,” said Howard Jonas,
chairman of Rafael Holdings, controlling shareholder of LipoMedix.
“I am pleased to welcome Miranda and Praveen to the board and look
forward to their contributions to help advance the company and its
lead product, Promitil®.”
Ms. Toledano has over 20 years of executive
experience in the biopharmaceutical sector. She is currently the
chief operating officer and chief financial officer of TRIGR
Therapeutics, a clinical stage immuno-oncology company focused on
bispecific antibodies. Previously, Ms. Toledano served as executive
vice president of corporate development at Sorrento Therapeutics.
From 2012-2016, Ms. Toledano served as head of healthcare
investment banking at MLV & Co. (acquired by B. Riley FBR &
Co.). Prior to joining MLV, Ms. Toledano served on the management
team at Royalty Pharma. Ms. Toledano started her career in Israel
where she led the Life Sciences Corporate Finance group at Ernst
& Young (Israel) from 1998 to 2003. Ms. Toledano holds a
Bachelor of Arts in economics from Tufts University and a Master of
Business Administration in finance and entrepreneurship from the
NYU Stern School of Business.
Dr. Tyle is currently the executive vice
president of research and development at Lexicon Pharmaceuticals, a
fully integrated biopharmaceutical company that is applying a
unique approach to gene science based on Nobel Prize-winning
technology to discover and develop precise medicines for people
with serious, chronic conditions. Prior to joining Lexicon, Dr.
Tyle was a member of the executive management team at Osmotica
Pharmaceuticals where he served as president, chief executive
officer and a member of the board of directors. Dr. Tyle has more
than 30 years of pharmaceutical industry experience and has held a
series of other senior leadership and executive positions where he
has advanced new medical device and drug candidate pipelines to
commercial success.
In addition to the board appointments, Alberto
Gabizon, M.D., Ph.D., co-founder of LipoMedix, will now serve as
president of the company and will continue to lead the scientific,
technological and clinical activities.
About LipoMedixLipoMedix is a
development-stage privately held company focused on the development
of an innovative, safe and effective cancer therapy based on
liposome delivery.
The Company was established to advance the
pharmaceutical and clinical development of a patented chemical
entity prodrug of mitomycin-C and its efficient delivery in
liposomes to cancer-affected target organs. This formulation, known
as Promitil® – Pegylated Liposomal Mitomycin-C Prodrug
(PL-MLP), overcomes problems associated with mitomycin-C toxicity
and turns it into a state-of-the-art anti-cancer drug that will
potentially become the therapy of choice in a variety of cancers,
especially those derived from the gastrointestinal tract (stomach,
pancreas, colorectal). The inventor of Promitil and scientific
founder of LipoMedix is Prof. Alberto Gabizon of the Hebrew
University – Shaare Zedek Medical Center. Dr. Gabizon is also
co-inventor and co-developer of Doxil®, (the first FDA-approved
nano-drug in cancer therapy). As co-developer of Doxil®, Prof.
Gabizon is one of the few scientists intimately familiar with the
successful development & commercialization process of liposomal
drugs.
Promitil® is an innovative chemotherapeutic
agent with distinct advantages over conventional anticancer agents
that have adverse side effects and lack selective delivery to
cancer affected sites. This innovative and breakthrough technology
has successfully completed phase 1A and 1B studies and will enable
cancer patients to receive safer therapy with a more potent
anti-tumor effect.
Safe Harbor StatementThis press
release contains forward-looking statements. These statements
relate to future events or the company’s future financial
performance. In some cases, you can identify forward-looking
statements by terminology such as "may", "will", "should",
"expect", "plan", "anticipate", "believe", "estimate", "predict",
"potential" or "continue", the negative of such terms, or other
comparable terminology. These statements are only predictions.
Actual events or results may differ materially from those in the
forward-looking statements as a result of various important
factors. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, such statements should
not be regarded as a representation by the company, or any other
person, that such forward-looking statements will be achieved. The
business and operations of the company are subject to substantial
risks which increase the uncertainty inherent in forward-looking
statements. We undertake no duty to update any of the
forward-looking statements, whether as a result of new information,
future events or otherwise.
In light of the foregoing, readers are cautioned
not to place undue reliance on such forward-looking statements.
###
Media Contact:Vanessa
Donohuerafael@antennagroup.com 201-465-8036
Rafael (NYSE:RFL)
Historical Stock Chart
From Apr 2024 to May 2024
Rafael (NYSE:RFL)
Historical Stock Chart
From May 2023 to May 2024